按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了北京天智航医疗科技股份有限公司（以下简称"贵公司"）2024 年 12 月 31 日 的财务报告内部控制的有效性。 北京天智航医疗科技股份有限公司 内部控制审计报告 上会师报字(2025)第 5828 号 上会会计师事务所（特殊普通合伙） 中国 上海 计师 李务所（特殊善通合伙） rtified Public Accountants (Special Genera 内部控制审计报告 上会师报字(2025)第 5828 号 北京天智航医疗科技股份有限公司全体股东: 会会计师 事务所（特殊普通合伙） 一、企业对内部控制的责任 anghai Certified Public Accountants (Special General Partnership) 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是贵公司董事会 的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审 计意见,并对注意到的非财务报告内部控制 ...

关于北京天智航医疗科技股份有限公司 2024 年度营业收入扣除事项的专项核查报告 上会师报字(2025)第 5832 号 上会会计师事务所（特殊普通合伙） 中国 上海 ·计师 穿 务所(特殊善通合伙) is Centilied Public Accountants (Shecial General Partner 关于北京天智航医疗科技股份有限公司 2024 年度营业收入扣除事项的专项核查报告 上会师报字(2025)第 5832 号 一、管理层的责任 北京天智航管理层的责任是提供真实、合法、完整的相关资料,按照《上海证 券交易所股票上市规则》(上证发〔2023〕127 号)及《上海证券交易所科创板股票上 市规则》(上证发〔2023〕128 号)及《科创板上市公司自律监管指南第 9 号 --- 财务 类退市指标: 营业收入扣除》(上证函〔2023〕3872 号)（适用上交所科创板上市公司 ) 的规定编制营业收入扣除情况表,并保证其内容真实、准确、完整,不存在虚假记 载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在实施核查工作的基础上对北京天智航管理层编制的营业收入扣 除情况表发表专项核查意见。我 ...

关于北京天智航医疗科技股份有限公司 募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 5830 号 上会会计师事务所（特殊普通合伙） 中国 上海 会会计师 事务所（特殊普通合伙） mahai Certified Public Accountants (Special General Partnership) 关于北京天智航医疗科技股份有限公司 2024 年度募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 5830 号 北京天智航医疗科技股份有限公司全体股东: 我们接受委托,对后附的北京天智航医疗科技股份有限公司(以下简称" 贵公司") 《关于 2024 年度公司募集资金存放与实际使用情况的专项报告》执行了鉴证工作。 一、管理层对募集资金专项报告的责任 按照中国证监会发布的《上市公司监管指引第 2 号一上市公司募集资金管理和 使用的监管要求(2022年修订)》(证监会公告(2022)15 号)和《上海证券交易所 科创板上市公司自律监管指引第 1 号--规范运作(2023 年 12 月修订)》(上证发(2023) 194 号）的规定编制《关于 2024 年度公司募集资金存放与实际使用情况的专 ...

北京天智航医疗科技股份有限公司 审计报告 上会师报字(2025)第 5827 号 上会会计师事务所（特殊普通合伙） 中国 上海 t and the 会会计师 事务所（特殊善通合伙） ai Certified Public Accountants (Special 审计报告 上会师报字(2025)第 5827 号 北京天智航医疗科技股份有限公司全体股东: 一、审计意见 我们审计了北京天智航医疗科技股份有限公司(以下简称"天智航公司"或"公 司"）财务报表,包括 2024年 12月 31 日的合并及公司资产负债表,2024年度的合 并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财 务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了天智航公司 2024年 12 月 31 目的合并及公司财务状况以及 2024 年度的合并 及公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于 ...

Financial Performance - The company reported a revenue of 178.84 million yuan for the reporting period, with a net loss attributable to shareholders of 121.13 million yuan, and a net loss of 169.74 million yuan after deducting non-recurring gains and losses[1]. - The company's operating revenue for 2024 was ¥178.84 million, a decrease of 14.85% compared to ¥210.04 million in 2023[21]. - The net profit attributable to shareholders of the listed company for 2024 was a loss of ¥121.13 million, an improvement from a loss of ¥156.39 million in 2023, representing a 22.54% reduction in losses[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 was a loss of ¥169.74 million, compared to a loss of ¥214.01 million in 2023[21]. - The company reported a significant increase in financial expenses by 140.54% to 7,041,614.45 RMB due to higher borrowing costs[95]. - The company reported a net loss of RMB 121.13 million for the fiscal year 2024, with no distributable profits available for shareholders[171]. Research and Development - Research and development expenses accounted for 65.34% of operating revenue in 2024, a decrease of 6.29 percentage points from 71.63% in 2023[22]. - The company has filed a total of 596 patents, including 232 invention patents, establishing a strong technological barrier in the orthopedic surgical robot field[44]. - The company has developed advanced core technologies, including high-precision online calibration with an error requirement of less than 0.5 mm, enhancing surgical safety and accuracy[70]. - The company has implemented multi-modal medical image fusion and processing technologies to improve surgical planning and execution, ensuring high precision in patient positioning[71]. - The company has achieved a significant increase in capitalized R&D investment, which rose by 208.66% to ¥31,251,363.52, reflecting the successful capitalization of new product development projects[85]. - Cumulative R&D investment over the last three fiscal years amounted to RMB 389.92 million, representing 71.54% of total revenue during that period[174]. Market Position and Strategy - The company aims to continuously expand its market share and accelerate the implementation of application scenarios, focusing on technological innovation and building an ecosystem centered around orthopedic surgical robots[1]. - The company is a leading enterprise in China's orthopedic surgical robot industry and was the first medical robot company to be listed on the Shanghai Stock Exchange's STAR Market in July 2020[56]. - The orthopedic surgical robot market is facing intense competition, and the company is focused on addressing challenges in new product and technology development[47]. - The company is actively pursuing international expansion but may face regulatory challenges that could impact product registration and operational licenses[55]. - The company has established a diversified revenue structure, transitioning from solely equipment sales to include sales of surgical tool kits and ongoing medical technology services[60]. - The orthopedic surgical robot market is projected to expand rapidly, with increasing recognition and acceptance among doctors and patients, leading to a broader customer base beyond first and second-tier cities[67]. Product Development and Innovation - The core product, the "Tianji" orthopedic surgical robot, has completed over 100,000 surgeries across more than 200 medical institutions in China, demonstrating excellent clinical application results[57]. - The company has developed multiple models of orthopedic surgical robots, with the "Tianji 1.0" receiving CFDA certification in 2016 and the "Tianji II" receiving NMPA certification in 2021[57]. - The company has developed an active optical tracking technology that enhances precision, miniaturization, durability, and reliability, which will be used in products launched from 2021 onwards[73]. - The company is focused on continuous innovation and development of its surgical robot technology, ensuring it remains competitive in a rapidly evolving market[66]. - The integration of new technologies such as 5G, AI, and virtual/augmented reality into surgical robots is expected to drive innovation and expand the application range of these devices[67]. Operational Efficiency - The net cash flow from operating activities increased by 42.14% year-on-year, reaching ¥18.07 million in the fourth quarter of 2024[23]. - The company has established a collaborative innovation mechanism with leading universities and hospitals, enhancing its research and development capabilities[41]. - The company is committed to improving the conversion rate of installed hospitals for orthopedic surgical robots and enhancing customer service efficiency[133]. - The company is focused on maintaining a high-quality, low-cost supply chain to ensure the availability of robots and consumables while adhering to regulatory requirements for product development[134]. - The company has implemented a stock incentive plan for 2024, granting 22,343,850 restricted stocks to 74 individuals, which is 21.83% of the total workforce[176]. Corporate Governance and Management - The company maintained strict compliance with corporate governance regulations, ensuring the protection of shareholder interests[137]. - The total pre-tax remuneration for key management personnel amounted to CNY 1,177.12 million for the reporting period[141]. - The remuneration for directors and senior management is composed of salary and bonuses[153]. - The company has not been subject to penalties from securities regulatory agencies in the past three years[155]. - The company held multiple board meetings in 2024 to discuss various proposals, including the use of idle fundraising for liquidity and capital increase for affiliated companies[156]. Environmental Responsibility - The company invested 5.24 million yuan in environmental protection during the reporting period[192]. - The company strictly adheres to national and local environmental protection laws, ensuring pollutant emissions meet relevant standards[194]. - The company promotes energy-saving and resource utilization, advocating a green office model[197]. - The company implements measures to reduce carbon emissions, including prioritizing electric vehicles for administrative use[198].

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥58,583,819.68, representing a 102.40% increase compared to ¥28,944,718.96 in the same period last year[4] - The net profit attributable to shareholders was -¥13,204,889.44, a decline from -¥10,063,239.85 year-on-year[4] - The basic and diluted earnings per share were both -¥0.03, a decrease of 50.00% compared to -¥0.02 in the previous year[4] - Net loss for Q1 2025 was ¥14,378,611.68, compared to a net loss of ¥10,063,239.85 in Q1 2024, indicating a worsening of 42.5%[20] Research and Development - Research and development (R&D) expenses totaled ¥28,838,595.82, accounting for 49.23% of revenue, down from 95.45% in the previous year, a decrease of 46.22 percentage points[5] - The company plans to continue focusing on R&D while managing costs to improve profitability in future quarters[8] - Research and development expenses for Q1 2025 were ¥25,323,317.05, slightly down from ¥25,891,190.61 in Q1 2024, indicating a decrease of 2.2%[18] Cash Flow and Liquidity - The net cash flow from operating activities improved by 71.30%, amounting to -¥14,337,816.54 compared to -¥49,952,267.09 in the same period last year[8] - Operating cash inflow for Q1 2025 totaled ¥82,390,014.85, compared to ¥54,280,843.27 in Q1 2024, representing an increase of 52%[20] - Cash outflow from operating activities in Q1 2025 was ¥96,727,831.39, a decrease from ¥104,233,110.36 in Q1 2024, showing a reduction of 7.2%[20] - The company reported a net increase in cash and cash equivalents of $17,662,284.60, compared to a decrease of -$31,834,713.79 in the prior period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,733,799,388.11, an increase of 2.49% from ¥1,691,716,774.29 at the end of the previous year[5] - Total liabilities as of the latest reporting period amounted to ¥413,580,571.19, slightly up from ¥411,577,279.87 in the previous period[16] - Non-current liabilities increased to ¥270,555,051.84 from ¥254,973,637.94, marking a rise of 6.1%[16] - The company's total equity reached ¥1,320,218,816.92, up from ¥1,280,139,494.42, reflecting a growth of 3.1%[16] Market and Product Development - The significant increase in revenue was attributed to higher sales of orthopedic surgical robots and increased income from providing technical services to medical institutions[8] - In Q1 2025, the Tianji orthopedic surgical robot performed over 11,000 surgeries, bringing the total to over 110,000 surgeries to date[12] - The orthopedic surgical navigation system received a Class III medical device registration certificate from the National Medical Products Administration, enhancing the company's product offerings and competitiveness[12] - The company aims to expand its product range to meet diverse clinical needs, enhancing its market position[12] - The company has established strategic partnerships to support market expansion and technological advancements[12] Non-Recurring Items - The company reported non-recurring gains of ¥18,041,873.99 after tax, primarily from government subsidies and other non-operating income[8] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[22]

北京天智航医疗科技股份有限公司 独立董事 2024 年度述职报告（李志勇） 本人作为北京天智航医疗科技股份有限公司（以下简称"公司"）的独立董事， 在 2024 年度，按照《公司法》《证券法》《上市公司治理准则》等法律法规、规 范性文件，以及《公司章程》和《独立董事工作制度》等相关规定，忠实履行职 责，在董事会日常工作及重要决策中尽职尽责，并对董事会的相关事项发表客观 的意见，从公司整体利益出发，发挥了独立董事的应有作用，维护了公司和全体 股东特别是中小股东的合法权益。现将 2024 年度本人履行独立董事职责的工作 情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 本人李志勇，1976 年出生，中国国籍，无境外永久居留权。EMBA，高级 信息系统项目管理师。曾任中国医学装备协会副秘书长。现任公司独立董事、中 国医学装备协会副理事长兼秘书长、中国医药健康产业股份有限公司独立董事。 （二）是否存在独立性情况说明 作为公司的独立董事，除在公司担任独立董事以外，本人及直系亲属均未在 公司或其附属企业任职，也未在公司主要股东担任任何职务，亦不存在为公司及 其控股股东或其各自的附属企业提供财 ...

北京天智航医疗科技股份有限公司 独立董事 2024 年度述职报告（徐扬） 本人作为北京天智航医疗科技股份有限公司（以下简称"公司"）的独立董事， 在 2024 年度，按照《公司法》《证券法》《上市公司治理准则》等法律法规、规 范性文件，以及《公司章程》和《独立董事工作制度》等相关规定，忠实履行职 责，在董事会日常工作及重要决策中尽职尽责，并对董事会的相关事项发表了客 观的意见，从公司整体利益出发，发挥了独立董事的应有作用，维护了公司和全 体股东特别是中小股东的合法权益。现将 2024 年度本人履行独立董事职责的工 作情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 本人徐扬，1967 年出生，中国国籍，无境外永久居留权。毕业于北京大学 法律系，中欧国际工商管理学院工商管理硕士。曾经担任中外运空运发展股份有 限公司独立董事、北方华创科技集团股份有限公司独立董事。现任北京市重光律 师事务所创始合伙人，主要专业领域涵盖项目融资、公司融资、资产重组与并购、 上市公司再融资与并购等。现任乐普（北京）医疗器械股份有限公司董事、唐山 港集团股份有限公司独立董事、西藏天路股份有限公司独立董事、公 ...

本人作为北京天智航医疗科技股份有限公司（以下简称"公司"）的独立董事， 在 2024 年度，按照《公司法》《证券法》《上市公司治理准则》等法律法规、 规范性文件，以及《公司章程》和《独立董事工作制度》等相关规定，忠实履行 职责，在董事会日常工作及重要决策中尽职尽责，并对董事会的相关事项发表了 客观的意见，从公司整体利益出发，发挥了独立董事的应有作用，维护了公司和 全体股东特别是中小股东的合法权益。现将 2024 年度本人履行独立董事职责的 工作情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 本人张瑞君，1961 年出生，中国国籍，无境外永久居留权。毕业于中国人 民大学，博士研究生学历。1992 年 12 月就职于中国人民大学，主要从事会计、 财务管理与信息技术相结合的交叉学科的研究和教学工作。中国人民大学商学院 教授、博士生导师、财政部会计信息化委员会咨询专家、中国会计学会会计信息 化专业委员会委员，中国注册会计师。2023 年 9 月起，任公司独立董事。 （二）是否存在独立性情况说明 作为公司的独立董事，除在公司担任独立董事以外，本人及直系亲属均未在 公司或其附属企业任职，也 ...